A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms OASIS-II
- 03 Mar 2022 Status changed from not yet recruiting to recruiting.
- 06 Dec 2021 Planned initiation date changed from 28 Sep 2021 to 28 Dec 2021.
- 31 Aug 2021 Planned initiation date changed from 28 Jul 2021 to 28 Sep 2021.